Buy Niva Bupa Health Insurance Ltd for the Target Rs 100 by Motilal Oswal Financial Services Ltd
Growth without compromise
* Niva Bupa (Niva) maintains its position as one of the fastest-growing retail health players, with growth trajectory improving from FY22-25 GWP CAGR of 27% to 35% YoY in FY26 (excluding 1/n) and market share of 10.1%. The growth remains above 30% in the first two months of FY27.
* While the retail health industry is likely to maintain a high-teen growth trajectory, Niva is expected to continue generating alpha over the industry growth, driven by superior customer experience, a diverse product suite and expanding agency network. Selective group health business (~30% of GWP) should contribute further to our expectation of 24% FY26-28 CAGR for insurance revenue (as per Ind AS).
* Niva's diversified distribution model (~30% of GWP contributed by agency, banca and brokers each) enables deeper customer penetration, superior resilience and sustained growth across market cycles. As health insurance penetration expands beyond metropolitan markets, this distribution platform is likely to become an increasingly important competitive advantage.
* About 60% of retail business originates from renewal business, which has superior economics (97-98% combined ratios) due to low acquisition costs. As the renewal book expands, persistency improves and profitability strengthens organically.
* Niva is focused on improving claims efficiency through better medical management, hospital engagement and standardized treatment protocols. Preferred provider networks and the use of technology are expected to improve claims predictability and reduce inefficiencies across the healthcare ecosystem. While the claims ratio should inch up to ~66% by FY28 (from 64.3% in FY26) owing to maturing client cohorts, these initiatives should support long-term loss ratio stability.
* On the back of investments in distribution, technology and brand building, Niva has reached a scale where revenue is increasingly growing faster than operating costs. Despite a modest increase in loss ratios, we expect the combined insurance service ratio (CISR) to improve to 100.1% by FY28 (101.4% in FY26), driven by structural cost efficiencies.
* Regulatory developments around EoM, commissions, solvency and IFRS reporting could materially reshape industry economics over the medium term. However, Niva’s diverse distribution mix positions the company relatively better within the evolving regulatory framework.
* We estimate a CAGR of 24%/28% in IFRS insurance revenue/PAT during FY26-28, with the CISR improving to 100.1% in FY28E. We maintain BUY rating on the stock with a TP of INR100 (valuing the company at 30x FY28E IFRS PAT).
Thoughtful investment management supports earnings stability
* Niva has adopted a deliberately conservative approach toward investment management, prioritizing capital preservation, balance sheet strength and earnings stability over short-term return maximization.
* The investment portfolio remains predominantly allocated toward fixed-income securities, with only a small proportion invested in equities through passive Nifty ETFs, which may not increase materially. The restrained allocation reflects a conscious desire to minimize earnings volatility.
* Under IFRS, mark-to-market movements in equity investments, AIFs and liquid mutual funds will flow through reported earnings, while the majority of debt investments will continue to generate accrual-based income with mark-tomarket changes recognized through other comprehensive income. Given Niva's limited exposure to market-sensitive assets, the transition is unlikely to introduce significant earnings volatility.
* Additionally, in the case of risk-based solvency, which is in the discussion phase, having a higher equity portion can lead to a higher risk allocation with respect to minimum solvency requirements.
* Stable investment yields at ~7%, along with improving underwriting performance, is expected to result in ~28% IFRS PAT CAGR over FY26-28, with RoE moving toward the mid-teen range gradually (10.7% in FY26).
Valuation and View
* Niva is entering the most attractive phase of the health insurance lifecycle, where scale, renewal accumulation, claims efficiency and operating leverage begin working simultaneously.
* The company continues to gain market share in a structurally underpenetrated industry while building a larger renewal base and improving profitability. With visibility on sustained 20%+ premium growth, improving CISR and a clear pathway toward mid-teen RoE, we believe Niva is evolving from a high-growth insurer into a high-quality compounding franchise.
* Beyond the core growth and profitability story, Niva benefits from several emerging tailwinds, including increasing health insurance awareness, premiumization of products, hospital protocol standardization and potential benefits from future commission regulation changes. Coupled with a conservative investment portfolio and strong capital position, these factors provide additional support to long-term earnings growth and return ratios.
* We estimate a CAGR of 24%/28% in IFRS insurance revenue/PAT during FY26-28, with the CISR improving to 100.1% in FY28E. We maintain BUY rating on the stock with a TP of INR100 (valuing the company at 30x FY28E IFRS PAT).
For More Research Reports : Click Here
For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH000000412
